Analysis of 501 melanoma exomes identified RASA2, encoding a RasGAP, as a tumor-suppressor gene mutated in 5% of melanomas. Recurrent loss-of-function mutations in RASA2 were found to increase RAS activation, melanoma cell growth and migration. RASA2 expression was lost in ≥30% of human melanomas and was associated with reduced patient survival. These findings identify RASA2 inactivation as a melanoma driver and highlight the importance of RasGAPs in cancer.
|Number of pages||3|
|Early online date||26 Oct 2015|
|Publication status||Published - Dec 2015|
FingerprintDive into the research topics of 'Recurrent inactivating RASA2 mutations in melanoma'. Together they form a unique fingerprint.
- Division of Biomedical Sciences - Reader in Genetics and Immunology
Person: Academic Research Active